Vaccines containing ribavirin and methods of use thereof

Details Vaccines containing ribavirin and methods of use thereof Vaccines containing ribavirin and methods of use thereof

2007-07-17

2007-07-17

Campell, Bruce R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S093100, C424S228100, C424S227100, C424S226100, C424S225100

Reexamination Certificate

active

11411493

ABSTRACT:
Compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans are disclosed. More particularly, vaccine compositions comprising ribavirin and an antigen, preferably an antigen that has an epitope present in Hepatitis C virus (HCV), are disclosed for use in treating and preventing disease, preferably HCV infection.

REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4950647 (1990-08-01), Robins et al.
patent: 5350671 (1994-09-01), Houghton et al.
patent: 5371017 (1994-12-01), Houghton et al.
patent: 5372928 (1994-12-01), Miyamura et al.
patent: 5585258 (1996-12-01), Houghton et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5597691 (1997-01-01), Houghton et al.
patent: 5670152 (1997-09-01), Weiner et al.
patent: 5670153 (1997-09-01), Weiner et al.
patent: 5679342 (1997-10-01), Houghton et al.
patent: 5683864 (1997-11-01), Houghton et al.
patent: 5698390 (1997-12-01), Houghton et al.
patent: 5712087 (1998-01-01), Houghton et al.
patent: 5712088 (1998-01-01), Houghton et al.
patent: 5712145 (1998-01-01), Houghton et al.
patent: 5714596 (1998-02-01), Houghton et al.
patent: 5728520 (1998-03-01), Weiner et al.
patent: 5756312 (1998-05-01), Weiner et al.
patent: 5767097 (1998-06-01), Tam
patent: 5856437 (1999-01-01), Miyamura et al.
patent: 5863719 (1999-01-01), Houghton et al.
patent: 5871903 (1999-02-01), Miyamura et al.
patent: 5885799 (1999-03-01), Houghton et al.
patent: 5932556 (1999-08-01), Tam
patent: 5942234 (1999-08-01), Ralston et al.
patent: 5959092 (1999-09-01), Miyamura et al.
patent: 5968775 (1999-10-01), Houghton et al.
patent: 5989905 (1999-11-01), Houghton et al.
patent: 6027729 (2000-02-01), Houghton et al.
patent: 6056961 (2000-05-01), Lavie et al.
patent: 6060068 (2000-05-01), Doyle et al.
patent: 6063380 (2000-05-01), Chedid et al.
patent: 6063772 (2000-05-01), Tam
patent: 6071693 (2000-06-01), Cha et al.
patent: 6074816 (2000-06-01), Houghton et al.
patent: 6074846 (2000-06-01), Ralston et al.
patent: 6074852 (2000-06-01), Ralston et al.
patent: 6096541 (2000-08-01), Houghton et al.
patent: 6130326 (2000-10-01), Ramasamy et al.
patent: 6150087 (2000-11-01), Chien
patent: 6150337 (2000-11-01), Tam
patent: 6171782 (2001-01-01), Houghton et al.
patent: 6190864 (2001-02-01), Cha et al.
patent: 6194140 (2001-02-01), Houghton et al.
patent: 6214583 (2001-04-01), Cha et al.
patent: 6235888 (2001-05-01), Pachuk et al.
patent: 6274148 (2001-08-01), Ralston et al.
patent: 6297370 (2001-10-01), Cha et al.
patent: 6303292 (2001-10-01), Weiner et al.
patent: 6312889 (2001-11-01), Houghton et al.
patent: 6514731 (2003-02-01), Valenzuela et al.
patent: 6541011 (2003-04-01), Punnonen et al.
patent: 6555114 (2003-04-01), Maertens et al.
patent: 6680059 (2004-01-01), Sallberg et al.
patent: 6762024 (2004-07-01), Maertens et al.
patent: 6858590 (2005-02-01), Sallberg et al.
patent: 6960569 (2005-11-01), Sallberg
patent: 6974864 (2005-12-01), Maertens et al.
patent: 7056658 (2006-06-01), Valenzuela et al.
patent: 7105303 (2006-09-01), Ralston et al.
patent: 7122306 (2006-10-01), Maertens et al.
patent: 2002/0165172 (2002-11-01), Sallberg et al.
patent: 2002/0187945 (2002-12-01), Tam
patent: 2003/0007977 (2003-01-01), Wheeler et al.
patent: 2003/0008274 (2003-01-01), Maeterns et al.
patent: 0 388 232 (1990-09-01), None
patent: 0 414 475 (1991-02-01), None
patent: 0 450 931 (1996-06-01), None
patent: 0 543 924 (1997-06-01), None
patent: 0 842 947 (1998-05-01), None
patent: 0 693 687 (1999-07-01), None
patent: 0 556 292 (1999-12-01), None
patent: 1 034 785 (2000-09-01), None
patent: 0 318 216 (2001-08-01), None
patent: 0 398 748 (2002-01-01), None
patent: WO 90/15070 (1990-12-01), None
patent: WO 91/15575 (1991-10-01), None
patent: WO 92/10092 (1992-06-01), None
patent: WO 92/19743 (1992-11-01), None
patent: WO 93/00365 (1993-01-01), None
patent: WO 93/06126 (1993-04-01), None
patent: WO 94/11530 (1994-05-01), None
patent: WO 94/12305 (1994-06-01), None
patent: WO 94/16737 (1994-08-01), None
patent: WO 95/11995 (1995-05-01), None
patent: WO 96/09805 (1996-04-01), None
patent: WO 96/28162 (1996-09-01), None
patent: WO 96/33739 (1996-10-01), None
patent: WO 97/12043 (1997-04-01), None
patent: WO 97/26883 (1997-07-01), None
patent: WO 97/29212 (1997-08-01), None
patent: WO 97/31256 (1997-08-01), None
patent: WO 97/47358 (1997-12-01), None
patent: WO 98/16184 (1998-04-01), None
patent: WO 98/16186 (1998-04-01), None
patent: WO 98/30223 (1998-07-01), None
patent: WO 98/34640 (1998-08-01), None
patent: WO 98/37180 (1998-08-01), None
patent: WO 99/04008 (1999-01-01), None
patent: WO 99/28482 (1999-06-01), None
patent: WO 00/44388 (2000-08-01), None
patent: WO 02/13855 (2001-02-01), None
patent: WO 01/38360 (2001-05-01), None
patent: WO 01/96875 (2001-12-01), None
patent: WO 02/14362 (2002-02-01), None
patent: WO 03/031588 (2003-04-01), None
Encke et al. J. Immunol. 1998, vol. 161, pp. 4917-4923.
Chiang et al. Vaccine Strategies Against Microbiol Pathogogen, Apr. 20, 2000, Abstract No. 42.14.
AASLD Abstracts 940, “Hepatitis C Virus NS5A Sequence Configuration does not Predict Response to Induction Interferon Plus Ribavinn,” Hepatology, p. 394A (2000).
Abrignani et al., “Perspectives for a vaccine against hepatitis C virus,” Journal of Hepatology, 31: (suppl. 1 ):259-263 (1999).
Andre et al., “Increased Immune Response Elicited by DNA Vaccination with a Synthetic gp120 Sequence with Optimized Codon Usage,” Journal of Virology, 72(2):1497-1503 (1998).
Bartenschlager et al., “Substrate Determinants for Cleavage in cis and in trans by the Hapatitis C Virus NS3 Proteinase,” Journal of Virology, pp. 198-205 (1995).
Bitter et al.,Methods in Enzymol., 153:516-544 (1987).
BLASTN 2.2.9., May 1, 2004.
Chang et al., Aliment Pharmacol Ther. Sep. 2002; 16(9): 1623-1632.
Chen et al., “Detection of Hepatitis C Virus RNA in the Cell Fraction of Saliva Before and After Oral Surgery,” J. Med. Virol., 43:223-226 (1995).
Chen et al., “Human and Murine Antibody Recognition is Focused on the ATPase/Helicase, but not the Protease Domain of the Hepatitis C Virus Nonstructural 3 Protein,” Hepatalogy, 28(1):219-224 (1998).
Colberre-Garapin, et al., “A new dominant hybrid selective marker for higher eukaryotic cells,”J. Mol. Biol. 150:1 (1981).
Cote et al., “Generation of human monoclonal antibodies reactive with cellular antigens”Proc Natl. Acad. Sci., 80:2026-2030 (1983).
Cotonat et al., “Pilot Study of Combination Therapy with Ribavirin and Interferon Alfa for the Retreatment of Chronic Hepatitis B e Antibody-Positive Patients”, Hepatology, 31(2):502-506 (2000).
Cramp et al., “Hepatitis C Virus-Specific T-Cell Reactivity During Intereron and Ribavirin Treatment in Chronic Hepatitis C,” Gastron. Enterol.,118:346-355 (2000).
Database Genbank [Online] Dec. 2, 1994, retrieved from NCBI Database accession No. IO6434, XP002278035.
Database Registry [Online] No. 511600-20-7, XP02278058 abstract & WO 03/031588A, Apr. 17, 2003, Seq ID No. 1, 10 and 11 Claims.
Davis et al.,Human Gene Therapy, 4(6):733 (1993).
Diepolder et al., “Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection,” Lancet, 346(8981):1006-1007, 1995.
Encke et al. Intervirology 1999, vol. 42, pp. 117-124.
Engvall, E.,Meth. Enzymol, 70:419 (1980).
Fang et al., “Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the Increased IL-12 level,” Journal of Hepatology, 33(5):791-798 (2000).
Fodor et al.,Science, 251:767-773 (1991).
Forns et al. PNAS 2000, vol. 97, pp. 13318-13323.
Forns et al., “Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resalving or persistent infection in chimpanzees,” PNAS, vol. 97, No. 24, pp. 13318-113323, (2000).
Gordon et al., “Immune responses to hepatitis C

Affiliated with

Also associated with

Rating

Vaccines containing ribavirin and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccines containing ribavirin and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccines containing ribavirin and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3770057